Personalized treatment approach for HER2-positive metastatic breast cancer.
Humans
Breast Neoplasms
/ pathology
Female
Receptor, ErbB-2
/ metabolism
Precision Medicine
/ methods
Neoplasm Metastasis
Antineoplastic Agents, Immunological
/ therapeutic use
Molecular Targeted Therapy
/ methods
Biomarkers, Tumor
/ metabolism
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Immunotherapy
/ methods
Anti-HER2
Breast cancer
HER2
Immunotherapy
Liquid biopsy
Locoregional
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
29
07
2024
accepted:
13
09
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
epublish
Résumé
Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.
Identifiants
pubmed: 39320608
doi: 10.1007/s12032-024-02504-4
pii: 10.1007/s12032-024-02504-4
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
252Subventions
Organisme : Science and Engineering Research Board
ID : SB/S9/Z-16/2016-IV (2022)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Yu Y, et al. Advances in antibody-drug conjugates in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2022;14:417–32.
pubmed: 36532256
Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri VJEO. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022. https://doi.org/10.1016/j.esmoop.2022.100409 .
doi: 10.1016/j.esmoop.2022.100409
pubmed: 35398607
pmcid: 9014390
Deepak P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol. 2020;59: 101837.
doi: 10.1016/j.jddst.2020.101837
Gradishar WJ, et al. "NCCN Guidelines® insights: breast cancer, version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484–93.
pubmed: 34794122
doi: 10.6004/jnccn.2021.0023
Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PJDDT. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discovery Today. 2022;27:2526.
pubmed: 35753642
doi: 10.1016/j.drudis.2022.06.007
P. Deepak et al., "c (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity," p. 123160, 2023.
Murthy RK, et al. Tucatinib, Trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
pubmed: 31825569
doi: 10.1056/NEJMoa1914609
Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–29.
pubmed: 27939064
doi: 10.1016/S0140-6736(16)32417-5
Koury J, et al. Immunotherapies: exploiting the immune system for cancer treatment. J Immunol Res. 2018;2018:9585614.
pubmed: 29725606
pmcid: 5872614
doi: 10.1155/2018/9585614
Pandey P, et al. αvβ3 integrin and folate-targeted pH-sensitive liposomes with dual ligand modification for metastatic breast cancer treatment. Bioengineering. 2024;11(8):800.
pubmed: 39199757
pmcid: 11352135
doi: 10.3390/bioengineering11080800
Ferrario C, Christofides A, Joy AA, Laing K, Gelmon K, Brezden-Masley C. Novel therapies for the treatment of HER2-positive advanced breast cancer: A Canadian perspective. Curr Oncol. 2022;29(4):2720–34.
pubmed: 35448196
pmcid: 9026432
doi: 10.3390/curroncol29040222
Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers. 2023;15(4):1320.
pubmed: 36831661
pmcid: 9954028
doi: 10.3390/cancers15041320
Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.
pubmed: 25693012
pmcid: 5584549
doi: 10.1056/NEJMoa1413513
Baselga J, et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med. 2011;366(2):109–19.
pubmed: 22149875
pmcid: 5705202
doi: 10.1056/NEJMoa1113216
Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.
pubmed: 28578601
doi: 10.1056/NEJMoa1706450
Gámez-Chiachio M, Sarrió D, Moreno-Bueno GJC. Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs. Cancers. 2022;14(18):4543.
pubmed: 36139701
pmcid: 9496705
doi: 10.3390/cancers14184543
Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.
pubmed: 32171426
doi: 10.1016/S1470-2045(19)30863-0
Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
pubmed: 11248153
doi: 10.1056/NEJM200103153441101
Nanda A, Pandey P, Rajinikanth P, Singh NJIJOBM. Revolution of nanotechnology in food packaging: Harnessing electrospun zein nanofibers for improved preservation-A review. Int J Biol Macromol. 2024. https://doi.org/10.1016/j.ijbiomac.2024.129416 .
doi: 10.1016/j.ijbiomac.2024.129416
pubmed: 38880456
Miles D, et al. "Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245–55.
pubmed: 34224826
doi: 10.1016/j.annonc.2021.06.024
Tripathy D, et al. De Novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist. 2020;25(2):e214–22.
pubmed: 32043771
doi: 10.1634/theoncologist.2019-0446
Wong Y, et al. Long-term survival of De Novo stage IV Human Epidermal Growth Receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313–8.
pubmed: 30139836
doi: 10.1634/theoncologist.2018-0213
Battisti NML, Tong D, Ring A, Smith I. "Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401–8.
pubmed: 31432365
doi: 10.1007/s10549-019-05406-6
Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE. "Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 2015;24(6):751–7.
pubmed: 26456898
doi: 10.1016/j.breast.2015.09.008
Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4(1):34.
pubmed: 31637013
pmcid: 6799843
doi: 10.1038/s41392-019-0069-2
Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. "Lapatinib for advanced or metastatic breast cancer. Oncologist. 2012;17(4):536–42.
pubmed: 22477724
pmcid: 3336826
doi: 10.1634/theoncologist.2011-0461
Lin NU, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10.
pubmed: 23601761
doi: 10.1016/j.breast.2013.03.006
Cardama GA, et al. Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. Crit Rev Oncol/Hematol. 2018;124:29–36.
pubmed: 29548483
doi: 10.1016/j.critrevonc.2018.01.012
Lavudi K, Nuguri SM, Pandey P, Kokkanti RR, Wang Q-E. ALDH and cancer stem cells: Pathways, challenges, and future directions in targeted therapy. Life Sci. 2024. https://doi.org/10.1016/j.lfs.2024.123033 .
doi: 10.1016/j.lfs.2024.123033
pubmed: 39222837
Deepak P, et al. Pentapeptide cRGDfK-surface engineered nanostructured lipid carriers as an efficient tool for targeted delivery of tyrosine kinase inhibitor for battling hepatocellular carcinoma. Int J Nanomed. 2023;18:7021–46.
doi: 10.2147/IJN.S438307
Baselga J, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.
pubmed: 25332247
doi: 10.1200/JCO.2013.54.5384
Loibl S, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016;27(8):1519–25.
pubmed: 27177864
pmcid: 6279074
doi: 10.1093/annonc/mdw197
Niikura N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593–9.
pubmed: 22124109
doi: 10.1200/JCO.2010.33.8889
Salgado R, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71.
pubmed: 25214542
doi: 10.1093/annonc/mdu450
Cortés J, et al. Efficacy and safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 2020;6(8):1203–9.
pubmed: 32584367
doi: 10.1001/jamaoncol.2020.1796
Saura C, et al. Neratinib Plus Capecitabine versus Lapatinib plus Capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49.
pubmed: 32678716
pmcid: 7499616
doi: 10.1200/JCO.20.00147
Narayan P, et al. US food and drug administration approval summary: Fam-Trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41(11):2108–16.
pubmed: 36780610
doi: 10.1200/JCO.22.02447
Tripathi D, et al. A promising approach of dermal targeting of antipsoriatic drugs via engineered nanocarriers drug delivery systems for tackling psoriasis. Drug Metab Bioanal Lett. 2023;16(2):89–104.
pubmed: 37534794
doi: 10.2174/2949681016666230803150329
Goldberg RM, et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 2018;3(4): e000353.
pubmed: 29765773
pmcid: 5950648
doi: 10.1136/esmoopen-2018-000353
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.
pubmed: 15864276
doi: 10.1038/nrc1609
Junttila TT, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429–40.
pubmed: 19411071
doi: 10.1016/j.ccr.2009.03.020
Diéras V, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42.
pubmed: 28526536
pmcid: 5531181
doi: 10.1016/S1470-2045(17)30312-1
André F, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.
pubmed: 31091374
doi: 10.1056/NEJMoa1813904
Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
pubmed: 23550210
pmcid: 4160307
doi: 10.1126/scisignal.2004088
Krop IE, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Cancers. 2014;15(7):689–99.
Nadal-Serrano M, et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers (Basel). 2020;12(3):670.
pubmed: 32183023
doi: 10.3390/cancers12030670
Xu Z, et al. Novel HER2-targeting antibody-drug conjugates of Trastuzumab beyond T-DM1 in breast cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019;183: 111682.
pubmed: 31563805
doi: 10.1016/j.ejmech.2019.111682
Saura C, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol. 2018;36:1014.
doi: 10.1200/JCO.2018.36.15_suppl.1014
Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21.
pubmed: 31825192
doi: 10.1056/NEJMoa1914510
Cortés J, et al. Trastuzumab Deruxtecan versus Trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54.
pubmed: 35320644
doi: 10.1056/NEJMoa2115022
Yardley DA, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756–64.
pubmed: 24743708
pmcid: 4037822
doi: 10.1038/bjc.2014.174
Witzel I, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—results from the HER-OS patient registry. BMC Cancer. 2014;14(1):806.
pubmed: 25371387
pmcid: 4230522
doi: 10.1186/1471-2407-14-806
Modi S, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.
pubmed: 35665782
pmcid: 10561652
doi: 10.1056/NEJMoa2203690
Lin NU, et al. Intracranial efficacy and survival with tucatinib plus Trastuzumab and Capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–9.
pubmed: 32468955
pmcid: 7403000
doi: 10.1200/JCO.20.00775
Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23–8.
pubmed: 17159499
doi: 10.1097/01.cad.0000236313.50833.ee
Swain SM, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–21.
pubmed: 24685829
pmcid: 4037862
doi: 10.1093/annonc/mdu133
Pestalozzi BC, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013;14(3):244–8.
pubmed: 23414588
doi: 10.1016/S1470-2045(13)70017-2
von Minckwitz G, et al. Trastuzumab Emtansine for Residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.
doi: 10.1056/NEJMoa1814017
Rugo HS, et al. Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–84.
pubmed: 33480963
doi: 10.1001/jamaoncol.2020.7932
Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021;2(2):139–55.
pubmed: 36046143
pmcid: 9400740
Kyriazoglou A, et al. Immunotherapy in HER2-positive breast cancer: a systematic review. Breast Care. 2022;17(1):63–70.
pubmed: 35355696
doi: 10.1159/000514860
Agostinetto E, et al. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers (Basel). 2022;14(9):2136.
pubmed: 35565264
doi: 10.3390/cancers14092136
You Z, et al. Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):489.
pubmed: 34526020
pmcid: 8442296
doi: 10.1186/s12935-021-02187-1
Schmid P, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.
pubmed: 30345906
doi: 10.1056/NEJMoa1809615
Szöőr Á, et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 2020;484:1–8.
pubmed: 32289441
doi: 10.1016/j.canlet.2020.04.008
Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther. 2014;22(5):1029–38.
pubmed: 24572294
pmcid: 4015244
doi: 10.1038/mt.2014.28
Arenas EJ, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021;12(1):1237.
pubmed: 33623012
pmcid: 7902842
doi: 10.1038/s41467-021-21445-4
Hegde M, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Inves. 2016;126(8):3036–52.
doi: 10.1172/JCI83416
Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–93.
pubmed: 28630051
pmcid: 5659200
doi: 10.1158/2159-8290.CD-17-0226
Tobias J, Garner-Spitzer E, Drinić M, Wiedermann U. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open. 2022;7(1): 100361.
pubmed: 35026721
pmcid: 8760406
doi: 10.1016/j.esmoop.2021.100361
Emens LA, et al. Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005–16.
pubmed: 33523233
pmcid: 8328980
doi: 10.1093/jnci/djab004
Salgado R, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448–54.
pubmed: 26181252
pmcid: 5551492
doi: 10.1001/jamaoncol.2015.0830
Holgado E, Perez-Garcia J, Gion M, Cortes J. Is there a role for immunotherapy in HER2-positive breast cancer? NPJ Breast Cancer. 2018;4:21.
pubmed: 30131972
pmcid: 6093898
doi: 10.1038/s41523-018-0072-8
Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
pubmed: 25428504
pmcid: 4836193
doi: 10.1038/nature14011
Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.
pubmed: 25034862
doi: 10.1016/S0140-6736(14)60958-2
Stewart R, et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62.
pubmed: 25943534
doi: 10.1158/2326-6066.CIR-14-0191
Boyerinas B, et al. Antibody-dependent cellular cytotoxicity activity of a novel Anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–57.
pubmed: 26014098
pmcid: 4739754
doi: 10.1158/2326-6066.CIR-15-0059
Loi S, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20(3):371–82.
pubmed: 30765258
doi: 10.1016/S1470-2045(18)30812-X
Emens LA, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–95.
pubmed: 33002436
doi: 10.1016/S1470-2045(20)30465-4
Criscitiello C, et al. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? Eur J Surg Oncol. 2015;41(10):1288–92.
pubmed: 26238477
doi: 10.1016/j.ejso.2015.07.013
Shien T, Terata K. Loco-regional therapy for metastatic breast cancer. Transl Cancer Res. 2020;9(8):5026–7.
pubmed: 35117866
pmcid: 8798899
doi: 10.21037/tcr-2020-mbc-13
Cardoso MJ, Mokbel K. Locoregional therapy in de novo metastatic breast cancer. The unanswered question. Breast. 2021;58:170–2.
pubmed: 34158166
pmcid: 8481928
doi: 10.1016/j.breast.2021.05.002
Khan SA, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol. 2020. https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA2 .
doi: 10.1200/JCO.2020.38.18_suppl.LBA2
pubmed: 33373276
pmcid: 8078252
Lee JS, Toktas O, Soran A. Role of locoregional treatment in De novo stage IV breast cancer. Clin Med Insights Oncol. 2020;14:1179554920942440.
pubmed: 32994701
pmcid: 7502854
doi: 10.1177/1179554920942440
Lo SS, et al. "Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54.
pubmed: 19997074
doi: 10.1038/nrclinonc.2009.188
Timmerman RD, Herman J, Cho LC. "Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.
pubmed: 25113761
pmcid: 4152712
doi: 10.1200/JCO.2014.55.4675
Thomas EM, et al. Breast Stereotactic Body Radiation Therapy (SBRT) reduces organ at risk exposure, treatment time and duration in partial breast irradiation. Int J Radiat Oncol Biol Phys. 2021. https://doi.org/10.1016/j.ijrobp.2021.07.750 .
doi: 10.1016/j.ijrobp.2021.07.750
pubmed: 34793726
pmcid: 8536231
S. J. Chmura et al., NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). vol. 40, pp. 1007-1007, 2022.
Jain SK, Dorn PL, Chmura SJ, Weichselbaum RR, Hasan Y. Incidence and implications of oligometastatic breast cancer. J Clin Oncol. 2012. https://doi.org/10.1200/jco.2012.30.15_suppl.e11512 .
doi: 10.1200/jco.2012.30.15_suppl.e11512
pubmed: 23150708
pmcid: 3413279
Kobayashi T, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–37.
pubmed: 22532161
doi: 10.1007/s12282-012-0347-0
Hanrahan EO, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas MD Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104(6):1158–71.
pubmed: 16047352
doi: 10.1002/cncr.21305
Krug D, et al. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90–6.
pubmed: 33912695
pmcid: 8065185
Freedman GM, Jones JA, Taunk NK. Stereotactic radiation for oligometastatic and oligoprogressive stage IV breast cancer: a case-based review. Curr Oncol. 2023;30(2):2510–23.
pubmed: 36826153
pmcid: 9955183
doi: 10.3390/curroncol30020192
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.
pubmed: 33473219
doi: 10.1038/s41571-020-00457-x
Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.
pubmed: 30410101
doi: 10.1038/s41576-018-0071-5
Tay TKY, Tan PH. Liquid biopsy in breast cancer: a focused review. Arch Pathol Lab Med. 2020;145(6):678–86.
doi: 10.5858/arpa.2019-0559-RA
Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet. 2019;95(6):643–60.
pubmed: 30671931
doi: 10.1111/cge.13514
Chen D, et al. Liquid biopsy applications in the clinic. Mol Diagn Ther. 2020;24(2):125–32.
pubmed: 31919754
doi: 10.1007/s40291-019-00444-8
De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40(3):172–86.
pubmed: 30736982
doi: 10.1016/j.tips.2019.01.006
Freitas AJA, et al. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. Int J Mol Sci. 2022;23(17):9952.
pubmed: 36077348
pmcid: 9456236
doi: 10.3390/ijms23179952
Ma S, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023;22(1):7.
pubmed: 36627698
pmcid: 9832643
doi: 10.1186/s12943-023-01715-z
Armakolas A, Kotsari M, Koskinas J. Liquid biopsies, novel approaches and future directions. Cancers (Basel). 2023;15(5):1579.
pubmed: 36900369
doi: 10.3390/cancers15051579
Jacot W, et al. Clinical correlations of programmed cell death ligand 1 status in liquid and standard biopsies in breast cancer. Clin Chem. 2020;66(8):1093–101.
pubmed: 32712650
doi: 10.1093/clinchem/hvaa121
Rodriguez BJ, et al. Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med. 2019;8(8):1183.
pubmed: 31394872
doi: 10.3390/jcm8081183
Bartnykaitė A, et al. Associations of MDM2 and MDM4 polymorphisms with early-stage breast cancer. J Clin Med. 2021;10(4):866.
pubmed: 33669778
pmcid: 7922970
doi: 10.3390/jcm10040866
Chin YM, et al. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021;112(1):454–64.
pubmed: 33075187
doi: 10.1111/cas.14697
Rothé F, et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO Phase III trial. Clin Cancer Res. 2019;25(12):3581–8.
pubmed: 30862692
doi: 10.1158/1078-0432.CCR-18-2521
Chen Z, et al. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Mol Genet Genomic Med. 2020;8(2): e1079.
pubmed: 31867841
doi: 10.1002/mgg3.1079
Turner NC, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296–308.
pubmed: 32919527
pmcid: 7599319
doi: 10.1016/S1470-2045(20)30444-7
André F, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208–17.
pubmed: 33246021
doi: 10.1016/j.annonc.2020.11.011
Cui X, et al. Breast cancer identification via modeling of peripherally circulating miRNAs. PeerJ. 2018;6: e4551.
pubmed: 29607263
pmcid: 5875392
doi: 10.7717/peerj.4551
Madhavan D, et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis. 2016;37(5):461–70.
pubmed: 26785733
doi: 10.1093/carcin/bgw008
Ozawa PMM, et al. Identification of miRNAs enriched in extracellular vesicles derived from serum samples of breast cancer patients. Biomolecules. 2020;10(1):150.
pubmed: 31963351
pmcid: 7022833
doi: 10.3390/biom10010150
Zou X, et al. Circulating miR-532-502 cluster derived from chromosome X as biomarkers for diagnosis of breast cancer. Gene. 2020;722: 144104.
pubmed: 31493506
doi: 10.1016/j.gene.2019.144104
Hirschfeld M, et al. Urinary exosomal MicroRNAs as potential non-invasive biomarkers in breast cancer detection. Mol Diagn Ther. 2020;24(2):215–32.
pubmed: 32112368
doi: 10.1007/s40291-020-00453-y
Chanteloup G, et al. Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study. J Extracell Vesicles. 2020;9(1):1766192.
pubmed: 32595915
pmcid: 7301715
doi: 10.1080/20013078.2020.1766192
Zou X, et al. MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis. Cancer Biomark. 2021;30(1):41–53.
pubmed: 32894240
doi: 10.3233/CBM-201547
Ortega FG, et al. Sandwich-type electrochemical paper-based immunosensor for Claudin 7 and CD81 dual determination on extracellular vesicles from breast cancer patients. Anal Chem. 2021;93(2):1143–53.
pubmed: 33301317
doi: 10.1021/acs.analchem.0c04180
Tian F, et al. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun. 2021;12(1):2536.
pubmed: 33953198
pmcid: 8100127
doi: 10.1038/s41467-021-22913-7
Todorova VK, et al. Circulating exosomal micrornas as predictive biomarkers of neoadjuvant chemotherapy response in breast cancer. Curr Oncol. 2022;29(2):613–30.
pubmed: 35200555
pmcid: 8870357
doi: 10.3390/curroncol29020055
Müller V, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6): 100299.
pubmed: 34839105
pmcid: 8637493
doi: 10.1016/j.esmoop.2021.100299
T. Fehm et al., Abstract PD3–12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial. Cancer Research, vol. 81, no. 4_Supplement, pp. PD3–12-PD3–12, 2021.
Wang C, et al. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020;181(3):679–89.
pubmed: 32367460
pmcid: 7299127
doi: 10.1007/s10549-020-05662-x
Jacot W, et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Res. 2019;21(1):121.
pubmed: 31727113
pmcid: 6854749
doi: 10.1186/s13058-019-1215-z
Pestrin M, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1):283–9.
pubmed: 22476856
doi: 10.1007/s10549-012-2045-1
Munzone E, et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer. 2012;12(5):340–6.
pubmed: 23040002
doi: 10.1016/j.clbc.2012.07.001
Allegretti M, et al. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer. 2021;20(1):151.
pubmed: 34839818
pmcid: 8628389
doi: 10.1186/s12943-021-01438-z
Kingston B, et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021;12(1):2423.
pubmed: 33893289
pmcid: 8065112
doi: 10.1038/s41467-021-22605-2
Davis AA, et al. Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine. 2020;58: 102914.
pubmed: 32707446
pmcid: 7381501
doi: 10.1016/j.ebiom.2020.102914
Liu J, et al. Circulating Tumor Cells (CTCs): A unique model of cancer metastases and non-invasive biomarkers of therapeutic response. Front Genet. 2021;12: 734595.
pubmed: 34512735
pmcid: 8424190
doi: 10.3389/fgene.2021.734595
Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014. https://doi.org/10.1126/scitranslmed.3007094 .
doi: 10.1126/scitranslmed.3007094
pubmed: 25122639
pmcid: 4399712
Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10):2877.
pubmed: 30248975
pmcid: 6213360
doi: 10.3390/ijms19102877
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24.
pubmed: 30796368
doi: 10.1038/s41571-019-0187-3
Abbosh C, et al. Correction: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2018;554(7691):264–264.
pubmed: 29258292
doi: 10.1038/nature25161
Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev. 2013;39(7):691–700.
pubmed: 23683721
doi: 10.1016/j.ctrv.2013.04.001
Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.
pubmed: 15317891
doi: 10.1056/NEJMoa040766
Giuliano M, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014;16(5):440.
pubmed: 25223629
pmcid: 4303121
doi: 10.1186/s13058-014-0440-8
Larsson AM, et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20(1):48.
pubmed: 29884204
pmcid: 5994056
doi: 10.1186/s13058-018-0976-0
Mu Z, et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015;154(3):563–71.
pubmed: 26573830
doi: 10.1007/s10549-015-3636-4
Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Rydén L. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16:433.
pubmed: 27390845
pmcid: 4938919
doi: 10.1186/s12885-016-2406-y
Galardi F, et al. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021;23(1):38.
pubmed: 33761970
pmcid: 7992319
doi: 10.1186/s13058-021-01415-w
Dirix L, et al. Circulating tumor cell detection: A prospective comparison between Cell Search® and RareCyte® platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022;193(2):437–44.
pubmed: 35397078
pmcid: 9090706
doi: 10.1007/s10549-022-06585-5
Kaldjian EP, et al. The RareCyte® platform for next-generation analysis of circulating tumor cells. Cytometry A. 2018;93(12):1220–5.
pubmed: 30277660
pmcid: 6586054
doi: 10.1002/cyto.a.23619
Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.
pubmed: 32979513
doi: 10.1016/j.annonc.2020.09.010